Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies

por Vasey, P A
Publicado 2003

Combined inhibition of topoisomerases I and II--is this a worthwhile/feasible strategy?

por Vasey, P. A., Kaye, S. B.
Publicado 1997

A phase II trial of capecitabine (Xeloda®) in recurrent ovarian cancer

por Vasey, P A, McMahon, L, Paul, J, Reed, N, Kaye, S B
Publicado 2003

The systemic inflammatory response, performance status and survival in patients undergoing alpha-interferon treatment for advanced renal cancer

por Bromwich, E, McMillan, D C, Lamb, G W A, Vasey, P A, Aitchison, M
Publicado 2004

Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours

por Thomson, A H, Vasey, P A, Murray, L S, Cassidy, J, Fraier, D, Frigerio, E, Twelves, C
Publicado 1999

A dose-finding study of carboplatin–epirubicin–docetaxel in advanced epithelial ovarian cancer

por O'Neill, V J, Kaye, S B, Reed, N S, Paul, J, Davis, J A, Vasey, P A
Publicado 2002

Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer

por Vasey, P A, Roché, H, Bisset, D, Terret, C, Vernillet, L, Riva, A, Ramazeilles, C, Azli, N, Kaye, S B, Twelves, C J
Publicado 2002

A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers

por Vasey, P A, Gore, M, Wilson, R, Rustin, G, Gabra, H, Guastalla, J-P, Lauraine, E P, Paul, J, Carty, K, Kaye, S
Publicado 2008

SCOTROC 2A: Carboplatin followed by docetaxel or docetaxel–gemcitabine as first-line chemotherapy for ovarian cancer

por Vasey, P A, Atkinson, R, Osborne, R, Parkin, D, Symonds, R, Paul, J, Lewsley, L, Coleman, R, Reed, N S, Kaye, S, Rustin, G J S
Publicado 2006

Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer

por Vasey, P A, Atkinson, R, Coleman, R, Crawford, M, Cruickshank, M, Eggleton, P, Fleming, D, Graham, J, Parkin, D, Paul, J, Reed, N S, Kaye, S B
Publicado 2001

Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent

por Lickliter, J D, Francesconi, A B, Smith, G, Burge, M, Coulthard, A, Rose, S, Griffin, M, Milne, R, McCarron, J, Yeadon, T, Wilks, A, Cubitt, A, Wyld, D K, Vasey, P A
Publicado 2010